{"url_path":"/sec/rklb/8-k/2026-06-29/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1819994/0001753926-26-001085-index.html","accession_number":"0001753926-26-001085","cik":"0001819994","ticker":"RKLB","issuer_name":"Rocket Lab Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819994/0001753926-26-001085-index.html","primary_entity_key":"0001819994","primary_entity_name":"Rocket Lab Corp"},"word_count":1664,"has_tables":true,"body_markdown":"**Item\n7.01. Regulation FD Disclosure.**\n\n \n\nOn\nJune 29, 2026, Rocket Lab and Iridium issued a joint press release announcing execution of the Merger Agreement. A copy of the\njoint press release is attached hereto and furnished herewith as Exhibit 99.1.\n\n \n\nIn\naddition, on June 29, 2026, Rocket Lab and Iridium released a joint investor presentation, which includes supplemental information\nabout the proposed transaction. A copy of the joint investor presentation is attached hereto and furnished herewith as Exhibit\n99.2.\n\n \n\nThe\ninformation set forth under this Item 7.01, Exhibit 99.1 and Exhibit 99.2 is not being filed for purposes of Section 18 of the\nExchange Act and is not to be incorporated by reference into any filing of the registrant under the Securities Act or the Exchange\nAct, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as\nshall be expressly set forth by specific reference in such a filing.\n\n \n\nAdditional\nInformation and Where to Find It\n\n \n\nThis\ncommunication is being made in respect of a proposed transaction involving Rocket Lab and Iridium. In connection with the proposed\ntransaction, Rocket Lab will file with the SEC a Registration Statement on Form S-4 that includes the proxy statement of Iridium\nthat will also constitute a prospectus of Rocket Lab. When the proxy statement/prospectus is finalized, it will be sent to the\nstockholders of Iridium seeking their approval of certain transaction-related proposals. This communication is not a substitute\nfor the proxy statement/prospectus or any other documents which Rocket Lab or Iridium may file with the SEC in connection with\nthe proposed transaction.\n\n \n\nRocket\nLab may not sell the common stock referenced in the proxy statement/prospectus until the Registration Statement on Form S-4 filed\nwith the SEC becomes effective. The preliminary proxy statement/prospectus and this communication are not offers to sell any securities,\nare not soliciting an offer to buy any securities in any state where the offer and sale is not permitted and are not a solicitation\nof any vote or approval.\n\n \n\n \n\n \n\n \n\nROCKET\nLAB AND IRIDIUM URGE INVESTORS AND SECURITY HOLDERS TO READ THE REGISTRATION STATEMENT ON FORM S-4, THE RELATED PROXY STATEMENT/PROSPECTUS\nINCLUDED THEREIN AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY\nWILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.\n\n \n\nInvestors\nand security holders will be able to obtain these materials (when they are available and filed) free of charge at the SEC’s\nwebsite, www.sec.gov. Copies of documents filed with the SEC by Rocket Lab (when they become available) may be obtained free of\ncharge on Rocket Lab’s website at https://investors.rocketlabcorp.com/financial-information/sec-filings or by contacting\nRocket Lab’s Investor Relations Department at investors@rocketlabusa.com. Copies of documents filed with the SEC by Iridium\n(when they become available) may be obtained free of charge on Iridium’s website at https://investor.iridium.com/sec-filings\nby contacting Iridium’s Investor Relations Department at investor.relations@iridium.com.\n\n \n\nParticipants\nin the Solicitation\n\n \n\nRobert\nH. Niehaus, Louis M. Alterman, Thomas C. Canfield, Matthew J. Desch, Thomas J. Fitzpatrick, L. Anthony Frazier, Suzanne E. McBride,\nEric T. Olson, Kay N. Sears, Monique S. Shivanandan and Jacqueline E. Yeaney, all of whom are members of Iridium’s board\nof directors, and Vincent J. O’Neill,\nIridium’s chief financial officer, may be considered participants in Iridium’s\nsolicitation. Information regarding such participants, including their direct or indirect interests, by security holdings or otherwise,\nwill be included in the proxy statement/prospectus and other relevant documents to be filed with the SEC in connection with the\ntransaction. Additional information about such participants is available under the captions “Proposal 1 – Election\nof Directors,” “Director Compensation” and “Security Ownership of Certain Beneficial Owners and Management”\nin Iridium’s definitive proxy statement in connection with its 2026 Annual\nMeeting of Stockholders (the “2026 Proxy Statement”), which was filed with the SEC on April 2, 2026 (which is available\nat https://www.sec.gov/ix?doc=/Archives/edgar/data/0001418819/000141881926000022/irdm-20260402.htm), as well as on Iridium’s\nAnnual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on February 12, 2026 (the\n“**2025 10-K”)** and certain of Iridium’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.\nTo the extent that holdings of Iridium’s securities have changed since the\namounts printed in the 2026 Proxy Statement, such changes have been or will be reflected on Statements of Change in Ownership\non Form 4 filed with the SEC (which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001418819).\nInformation regarding Iridium’s transactions with related persons is set forth\nin the 2026 Proxy Statement under the caption “Transactions with Related Parties,” as well as on the 2025 10-K and\ncertain of Iridium’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Certain illustrative information regarding\nthe payments to that may be owed, and the circumstances in which they may be owed, by Iridium to\nits named executive officers in a change of control of Iridium is set forth in the\n2026 Proxy Statement under the caption “Severance and Change in Control-Related Benefits,” as well as on the 2025\n10-K and certain of Iridium’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Rocket Lab may also be deemed\nto be a participant in Iridium’s solicitation; information regarding Rocket\nLab will be included in the proxy statement/prospectus and other relevant documents to be filed with the SEC in connection with\nthe transaction. Copies of these documents may be obtained, free of charge, from the SEC or Iridium as\ndescribed in the preceding paragraph.\n\n \n\n \n\n \n\n \n\nCautionary\nNote Regarding Forward-Looking Statements\n\n \n\nThis\ncommunication contains “forward-looking statements” within the meaning of the federal securities laws. These forward-looking\nstatements are based on Rocket Lab’s and Iridium’s current expectations, estimates and projections about the expected\ndate of closing of the proposed transaction and the potential benefits thereof, its business and industry, management’s\nbeliefs and certain assumptions made by Rocket Lab and Iridium, all of which are subject to change. In this context, forward-looking\nstatements often address expected future events, including future business and financial performance and financial condition.\nAll forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond\nour control, and are not guarantees of future results, such as statements about the consummation of the proposed transaction and\nthe anticipated benefits thereof. These and other forward-looking statements are not guarantees of future results and are subject\nto risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied in\nany forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ\nmaterially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements\nand caution must be exercised in relying on forward-looking statements. Important risk factors that may cause such a difference\ninclude, but are not limited to: (i) the completion of the proposed transaction on anticipated terms and timing, or at all, including\nobtaining stockholder and regulatory approvals and satisfying other conditions to the completion of the transaction; (ii) the\noccurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, including\nthe receipt by Iridium of an unsolicited proposal from a third party; (iii) failure to realize the anticipated benefits of the\nproposed transaction on a timely basis or at all, including anticipated tax treatment, unforeseen liabilities, future capital\nexpenditures, revenues, expenses, earnings, the integration of the businesses of Rocket Lab and Iridium, synergies, economic performance,\nindebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion\nand growth of Rocket Lab’s and Iridium’s businesses; (iv) Rocket Lab’s and Iridium’s ability to implement\ntheir business strategies; (v) potential litigation relating to the proposed transaction that could be instituted against Rocket\nLab, Iridium or their respective directors, managers, or officers, including the effects of any outcomes related thereto; (vi)\nthe risk that disruptions from the proposed transaction will harm Rocket Lab’s or Iridium’s businesses, including\ncurrent plans and operations, or will otherwise divert management time from ongoing business operations on transaction-related\nissues; (vii) the ability of Rocket Lab or Iridium to retain and hire key personnel; (viii) potential adverse reactions or changes\nto business relationships resulting from the announcement or completion of the proposed transaction; (ix) fluctuations in, and\nuncertainty as to the long-term value of, Rocket Lab or Iridium common stock (including as relating to the risk that any announcements\nrelated to the proposed transaction could have adverse effects on the market price of such stock); (x) legislative, regulatory\nand economic developments affecting Rocket Lab’s and Iridium’s businesses, including actions by government agencies\nand third parties; (xi) general economic and market developments and conditions, potential changes to international trade relations,\ngeopolitical conflicts and effects from global pandemics, epidemics, or other public health crises; (xii) the evolving legal,\nregulatory and tax regimes under which Rocket Lab and Iridium operate; (xiii) restrictions during the pendency of the proposed\ntransaction that may impact Rocket Lab’s or Iridium’s ability to pursue certain business opportunities or strategic\ntransactions; (xiv) unexpected costs, charges or expenses resulting from the proposed transaction; (xv) risks that any debt or\nother financing anticipated in connection with the proposed transaction is not obtained or that such financing cannot be obtained\non the anticipated timing or terms or unexpected costs or expenses in connection therewith; and (xvi) the other risks and uncertainties,\nas described in the periodic reports that Rocket Lab and Iridium file with the SEC. These risks, as well as other risks associated\nwith the proposed transaction, are more fully discussed in the proxy statement/prospectus to be filed with the SEC in connection\nwith the proposed transaction. Neither Rocket Lab nor Iridium assumes any obligation to publicly provide revisions or updates\nto any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances\nchange, except as otherwise required by securities and other applicable laws. Forward-looking statements included in this communication\nare made as of the date of this communication."}